Cetuximab plus 5‐fluorouracil in patients with advanced cutaneous squamous cell carcinoma: a retrospective cohort study
For patients with advanced cSCC who are contraindicated to or have progressed on first-line cemiplimab, combination of cetuximab and 5-FU is a well-tolerated but limited treatment option.
Authors
- Julia Huynh (ORCID: https://orcid.org/0000-0002-2357-4184)
- Max Schlaak (ORCID: https://orcid.org/0000-0002-1663-8098)
- Rose K. C. Moritz (ORCID: https://orcid.org/0000-0001-7102-8762)
- Thomas Eigentler (ORCID: https://orcid.org/0000-0003-0019-2770)
- Gabriela Poch (ORCID: https://orcid.org/0000-0003-3948-2505)
- Gábor Dobos (ORCID: https://orcid.org/0000-0002-2544-7197)
Institutions
- Humboldt-Universität zu Berlin (DE)
- Freie Universität Berlin (DE)
- Charité - Universitätsmedizin Berlin (DE)
Publication Details
- Journal
- JDDG Journal der Deutschen Dermatologischen Gesellschaft
- Published
- 2025-05-23
- DOI
- https://doi.org/10.1111/ddg.15695
- Primary Topic
- Nonmelanoma Skin Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00